Medicine and Dentistry
Patient
56%
Gemcitabine
48%
Prostate Cancer
46%
Morbidity
44%
Therapeutic Procedure
40%
Inpatient
37%
Urinary System
29%
Cisplatin
28%
Prostatectomy
25%
Progressive Disease
25%
Placebo
25%
Arm
22%
Radiation Therapy
22%
Incidence
19%
Adverse Event
19%
Prostate Specific Membrane Antigen
18%
Lutetium 177
17%
Bone Scintigraphy
17%
PET-CT
15%
Progression Free Survival
14%
Carboplatin
12%
Combination Therapy
11%
Famotidine
10%
Overall Survival
10%
Relapse
9%
Follow up
7%
Cancer Therapy
6%
Prevalence
6%
Pelvis
6%
Castration Resistant Prostate Cancer
6%
Surveillance
5%
Hormone Therapy
5%
Functional Assessment
5%
Maintenance Therapy
5%
Brief Pain Inventory
5%
Docetaxel
5%
Group Therapy
5%
Quality of Life
5%
Clinical Trial
5%
Nursing and Health Professions
Patient
100%
Gemcitabine
48%
Morbidity
44%
Prostate Cancer
43%
Quality of Life
29%
Cisplatin
28%
Prostatectomy
25%
Radiotherapy
22%
Inpatient
20%
Data Base
20%
Prostate Specific Membrane Antigen
18%
Patient-Reported Outcome
18%
Health Care Quality
17%
Bone Scintiscanning
17%
Lutetium 177
17%
Incidence
14%
Adverse Event
13%
Physician
12%
Carboplatin
12%
Famotidine
10%
Relapse
9%
Chemotherapy
8%
Dose
8%
Follow up
7%
Time
7%
Prevalence
6%
Progression Free Survival
6%
Confidence Interval
6%
Hormonal Therapy
5%
Group Therapy
5%
Symptom
5%
Overall Survival
5%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
48%
Prostate Cancer
46%
Morbidity
44%
Cisplatin
28%
Adverse Event
19%
Incidence
18%
Lutetium 177
17%
Progression Free Survival
14%
Carboplatin
12%
Famotidine
10%
Chemotherapy
10%
Overall Survival
9%
Clinical Trial
8%
Prevalence
6%
Castration Resistant Prostate Cancer
6%
Docetaxel
5%
Symptom
5%